Statements (26)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
gptkb:drug |
| gptkbp:administeredBy |
oral
|
| gptkbp:approvalYear |
2010
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
N07XX07
|
| gptkbp:CASNumber |
504-24-5
|
| gptkbp:chemicalFormula |
C5H6N2
|
| gptkbp:developedBy |
gptkb:Acorda_Therapeutics
|
| gptkbp:eliminatedIn |
gptkb:kidney
|
| gptkbp:hasSMILES |
c1cc(ncc1N)
|
| https://www.w3.org/2000/01/rdf-schema#label |
fampridine
|
| gptkbp:improves |
walking in multiple sclerosis patients
|
| gptkbp:IUPACName |
gptkb:4-aminopyridine
|
| gptkbp:marketedAs |
gptkb:Ampyra
gptkb:Fampyra |
| gptkbp:mechanismOfAction |
potassium channel blocker
|
| gptkbp:metabolism |
liver
|
| gptkbp:molecularWeight |
94.11 g/mol
|
| gptkbp:sideEffect |
dizziness
urinary tract infection seizures insomnia |
| gptkbp:usedFor |
multiple sclerosis
|
| gptkbp:bfsParent |
gptkb:Fampyra
|
| gptkbp:bfsLayer |
6
|